Fabre et al., found that blocking either IL-22 or IL-17 production in a mouse model resulted in fibrosis amelioration, thus identifying a pathogenic role of IL-17 and IL-22 in driving liver fibrosis [43]. This evidence concerns the gene IL22 and Hepatic fibrosis.